Related news from
Fri, 26 Apr 2024 15:27:00 +0000	Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates Sage Therapeutics' (SAGE) first-quarter 2024 results are mixed as earnings miss estimates, but sales beat the mark. The newly-launched depression drug Zurzuvae drives the company's top line.
Tue, 23 Apr 2024 12:31:00 +0000	Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 JUPITER, Fla., April 23, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, May 7, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same day to discuss financial results and provide a general business update.
Wed, 17 Apr 2024 13:55:05 +0000	Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know The average of price targets set by Wall Street analysts indicates a potential upside of 45.6% in Ligand (LGND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Tue, 16 Apr 2024 16:47:00 +0000	Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why Aptevo (APVO) plunges after it issues secondary shares, which are not only issued at a significant discount but also substantially dilute the existing shareholder base.
Tue, 16 Apr 2024 15:46:00 +0000	Marinus (MRNS) Down 83% on Lead Drug Falling Short in Seizure Study Interim results from a late-stage study show that Marinus' (MRNS) ganaxolone failed to meet the pre-specified stopping criteria in patients with refractory status epilepticus.
Mon, 15 Apr 2024 17:01:00 +0000	Enlivex (ENLV) Stock Plummets 51% in a Week: Here's Why Enlivex (ENLV) plunges after it shares mixed results from a mid-stage study evaluating its lead drug as a potential treatment for sepsis.
Tue, 09 Apr 2024 17:34:00 +0000	Vincerx (VINC) Tumbles on Results From Cancer Therapy Study Though early-stage results on Vincerx's (VINC) experimental drug did show signs of anti-tumor activity, the share price drops as some analysts stated that the results were below expectations.
Tue, 09 Apr 2024 15:09:00 +0000	Corcept (CORT) Completes Enrollment in Ovarian Cancer Study The phase III ROSELLA study is evaluating Corcept's (CORT) relacorilant plus nab-paclitaxel for treating recurrent, platinum-resistant ovarian cancer. Enrollment in the study has been completed.
Tue, 09 Apr 2024 12:59:00 +0000	Palatin (PTN) Up 15% on Results From Dry Eye Disease Study A late-stage study data shows that treatment with Palatin's (PTN) experimental dry eye disease drug achieved statistically significant and clinically meaningful improvements across multiple symptom endpoints.
Tue, 09 Apr 2024 10:31:56 +0000	Can Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Performance Keep Up Given Its Mixed Bag Of Fundamentals? Ligand Pharmaceuticals' (NASDAQ:LGND) stock is up by 8.4% over the past three months. However, we decided to study the...
Mon, 08 Apr 2024 17:51:00 +0000	Iovance (IOVA) Stock Surges More Than 60% YTD: Here's Why Iovance (IOVA) surges on the recent FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.
Mon, 08 Apr 2024 12:15:00 +0000	Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference LONDON, April 08, 2024--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partners at the University of Minnesota (UMN) and CURx Pharmaceuticals, Inc. presented new data on Captisol-enabled™ Topiramate Injection (IV topiramate), a potential replacement therapy for the treatment of certain emergent neurological conditions, including epilepsy, when oral administration is not feasible.
Mon, 08 Apr 2024 10:59:00 +0000	MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why MindMed's (MNMD) progress with the development of its lead candidate MM120 for treating generalized anxiety disorder has been encouraging, leading the stock to rise during this time.
Fri, 05 Apr 2024 22:00:21 +0000	Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts Ligand Pharmaceuticals (LGND) closed at $77.96 in the latest trading session, marking a -0.03% move from the prior day.
Thu, 04 Apr 2024 17:32:00 +0000	Gritstone (GRTS) Plummets 58% in a Week: Here's Why Gritstone (GRTS) plunges after a mid-stage study evaluating its personalized cancer vaccine in certain patients with colorectal cancer failed to achieve its primary endpoint.
Thu, 04 Apr 2024 17:20:00 +0000	Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.
Thu, 04 Apr 2024 13:30:11 +0000	Wall Street Analysts Think Ligand (LGND) Is a Good Investment: Is It? According to the average brokerage recommendation (ABR), one should invest in Ligand (LGND). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Thu, 04 Apr 2024 13:00:11 +0000	Investors Heavily Search Ligand Pharmaceuticals Incorporated (LGND): Here is What You Need to Know Zacks.com users have recently been watching Ligand (LGND) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Wed, 03 Apr 2024 15:32:00 +0000	EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.
Wed, 03 Apr 2024 13:00:00 +0000	Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™ JUPITER, Fla. & DURHAM, N.C., April 03, 2024--Ligand Pharmaceuticals (Nasdaq: LGND) today announced the launch of Pelthos Therapeutics (Pelthos), a biopharmaceutical company, and the appointment of seasoned industry executive Scott Plesha to the role of Chief Executive Officer.